HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept

[1]  R. Orvieto.  Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma , 2013, Journal of Ovarian Research.

[2]  B. Ata,et al.  Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. , 2013, Human reproduction.

[3]  E. Papanikolaou,et al.  Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. , 2013, Fertility and sterility.

[4]  P. Humaidan,et al.  GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.

[5]  R. Orvieto.  Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? , 2012, Reproductive biomedicine online.

[6]  P. Devroey,et al.  The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. , 2012, Reproductive biomedicine online.

[7]  P. Humaidan,et al.  1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. , 2010, Fertility and sterility.

[8]  E. Kolibianakis,et al.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. , 2006, Human reproduction update.

[9]  A. Arroliga,et al.  Ovarian hyperstimulation syndrome , 2005, Critical care clinics.

[10]  R. Orvieto.  Can we eliminate severe ovarian hyperstimulation syndrome? , 2004, Human reproduction.

[11]  Z. Ben-Rafael,et al.  Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. , 1998, Human reproduction.

[12]  Z. Ben-Rafael,et al.  Ovarian Hyperstimulation Syndrome: A New Insight Into an Old Enigma , 1998, The Journal of the Society for Gynecologic Investigation: JSGI.

[13]  Z. Shoham,et al.  Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. , 1996, Human reproduction.

[14]  V. Wiwanitkit,et al.  Ovarian hyperstimulation syndrome , 1991, The Lancet.

[15]  A. Zeleznik,et al.  The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. , 1985, Endocrinology.

[16]  D. Bromham,et al.  The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle ("ovulation") derived form treated and untreated conception cycles. , 1982, Fertility and sterility.

[17]  J. Nulsen,et al.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. , 2008, Fertility and sterility.

[18]  E. Anteby,et al.  Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols. , 2006, Reproductive biomedicine online.

[19]  A. Birmingham,et al.  The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology , 2006 .

[20]  S. Kol.  Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. , 2004, Fertility and sterility.